NASDAQ:ONCE - Spark Therapeutics Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $50.89 -0.20 (-0.39 %) (As of 02/20/2019 04:00 PM ET)Previous Close$51.09Today's Range$49.79 - $51.6452-Week Range$34.53 - $96.59Volume396,554 shsAverage Volume469,237 shsMarket Capitalization$1.92 billionP/E Ratio-6.67Dividend YieldN/ABeta2.06 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Spark Therapeutics (NASDAQ:ONCE) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.20 Wall Street analysts have issued ratings and price targets for Spark Therapeutics in the last 12 months. Their average twelve-month price target is $65.9474, suggesting that the stock has a possible upside of 29.59%. The high price target for ONCE is $85.00 and the low price target for ONCE is $40.00. There are currently 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyBuyHoldConsensus Rating Score: 2.602.602.572.43Ratings Breakdown: 0 Sell Rating(s)8 Hold Rating(s)12 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)8 Hold Rating(s)12 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)9 Hold Rating(s)12 Buy Rating(s)0 Strong Buy Rating(s)2 Sell Rating(s)8 Hold Rating(s)11 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $65.9474$65.7895$66.55$72.15Price Target Upside: 29.59% upside48.91% upside70.64% upside25.07% upsideSpark Therapeutics (NASDAQ:ONCE) Consensus Price Target History Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails2/19/2019Credit Suisse GroupReiterated RatingHold$47.00Low2/19/2019William BlairReiterated RatingBuyLow2/17/2019Cantor FitzgeraldReiterated RatingBuy$80.00High11/26/2018Raymond JamesReiterated RatingBuyMedium11/7/2018MizuhoLower Price TargetBuy$62.00Medium11/7/2018BMO Capital MarketsLower Price TargetMarket Perform$48.00High11/7/2018B. RileyUpgradeNeutral ➝ Buy$68.00 ➝ $71.00High11/7/2018WedbushUpgradeUnderperform ➝ Neutral$40.00 ➝ $40.00High11/7/2018JPMorgan Chase & Co.Reiterated RatingHold$60.00High10/9/2018GuggenheimInitiated CoverageBuy ➝ Buy$70.00High8/8/2018SunTrust BanksLower Price TargetBuy$61.00Low8/8/2018UBS GroupLower Price TargetNeutral ➝ Neutral$80.00 ➝ $53.00Medium8/8/2018BarclaysLower Price TargetOverweight ➝ Overweight$85.00 ➝ $77.00Medium8/8/2018Royal Bank of CanadaLower Price TargetSector Perform$64.00High8/8/2018Stifel NicolausLower Price TargetBuy ➝ Buy$76.00 ➝ $68.00Medium8/8/2018Chardan CapitalBoost Price TargetNeutral$60.00 ➝ $85.00Medium8/7/2018Leerink SwannReiterated RatingMarket Perform$74.00 ➝ $55.00Medium8/7/2018CitigroupUpgradeNeutral ➝ BuyHigh5/8/2018CowenReiterated RatingBuy$85.00High2/21/2018Sanford C. BernsteinReiterated RatingBuy$71.00 ➝ $60.00Low12/14/2017Goldman Sachs GroupDowngradeBuy ➝ Neutral$106.00 ➝ $58.00Low10/10/2017Jefferies Financial GroupReiterated RatingBuy$95.00N/A8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$83.00High(Data available from 2/20/2017 forward) This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: What is the quiet period?